
https://www.science.org/content/blog-post/more-thiol-reactive-pain-compounds
# More Thiol-Reactive PAIN Compounds (February 2015)

## 1. SUMMARY
This article discusses an open-access *Journal of Medicinal Chemistry* paper from researchers at Mayo Clinic, University of Minnesota, and AstraZeneca about problematic compounds in high-throughput screening (HTS). The researchers were screening for antifungal targets using the Rtt109 histone acyltransferase enzyme with a fluorescent CPM probe, but encountered severe problems with assay interference.

Out of approximately 1,500 primary screening hits, only three compounds were real actives—the rest were false positives caused by various forms of assay interference. Many hit compounds were thiol-reactive PAINS (Pan-Assay Interference Compounds) that reacted with protein cysteines or assay components like CoA byproducts, rather than genuinely inhibiting the target. The authors identified multiple interference mechanisms including addition-elimination reactions, nucleophilic aromatic substitution, buffer instability, disulfide bond formation, and hydrogen peroxide production. Critically, many of these problematic compounds escaped existing cheminformatic PAINS filters, highlighting the limitations of purely computational triage methods.

## 2. HISTORY
The 2015 article addressed a critical issue in drug discovery that continued to evolve significantly in subsequent years. The problem of PAINS and assay interference compounds became increasingly recognized as a major challenge in early drug discovery, leading to concrete developments:

**Scientific Impact:** The recognition of PAINS led to major methodological changes in drug discovery workflows. Many pharmaceutical companies and academic screening centers implemented more rigorous experimental counter-screening protocols, moving beyond purely computational filters. Techniques like NMR-based binding assays, thermal shift assays, and orthogonal biochemical assays became standard practice for validating HTS hits. Companies increasingly required multiple orthogonal assays before advancing compounds, significantly reducing false-positive-driven research programs.

**Technology Development:** The PAINS concept spurred development of better computational tools. Academic groups developed more sophisticated filters that went beyond simple substructure matching, incorporating reactivity predictions and mechanistic considerations. Databases were expanded to include the new thiol-reactive compound classes identified in the 2015 paper and similar publications.

**Publication and Database Evolution:** The PAINS concept became institutionalized in drug discovery. Major journals implemented more stringent requirements for characterizing compound interference before publication of screening results. Public databases incorporated PAINS flags, and many compound vendors began explicitly identifying and removing PAINS compounds from screening libraries.

**Business Impact:** The heightened awareness of PAINS affected compound library design and screening strategies. Companies realized that larger screening libraries with higher PAINS content could be counterproductive, leading to more curated, higher-quality screening collections. However, there was no significant FDA policy change specifically around PAINS, as this primarily affects pre-clinical discovery rather than regulatory approval processes.

## 3. PREDICTIONS
The article made several implicit and explicit predictions about the future of HTS and drug discovery, which largely proved accurate:

• **Computational filter limitations**: The article predicted that cheminformatic PAINS filters would prove insufficient and that many problematic compounds would escape detection. This was confirmed by subsequent research showing that computational filters often miss context-dependent interference mechanisms.
  
• **Need for experimental validation**: The prediction that screening centers would need to adopt more experimental, chemistry-centric approaches to hit triage proved accurate. Modern drug discovery workflows now routinely include extensive counter-screening and orthogonal validation methods.
  
• **Impact on inexperienced researchers**: The concern that inexperienced HTS personnel over-reliant on computational filters would waste significant resources proved well-founded. This became a recognized training issue in drug discovery programs, leading to better educational resources and protocols.
  
• **Wider adoption of detection techniques**: The recommendation that the paper's counter-screening methods should be more widely heeded was largely realized, with many of these techniques becoming standard practice in the field.

## 4. INTEREST
Rating: **8/10**

This article addresses a fundamental and persistent challenge in drug discovery with significant practical impact, particularly for HTS practitioners and medicinal chemists. While focused on a specific technical issue, it highlights a broader theme about experimental validation versus computational shortcuts that remains highly relevant.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20150202-more-thiol-reactive-pain-compounds.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_